Pliant Therapeutics
PLRX
88 hedge funds and large institutions have $416M invested in Pliant Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 13 reducing their positions, and 7 closing their positions.
162% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 13
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
14% more funds holding
Funds holding: 77 → 88 (+11)
1.08% more ownership
Funds ownership: 84.53% → 85.61% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
19% less capital invested
Capital invested by funds: $512M → $416M (-$96M)
50% less call options, than puts
Call options by funds: $326K | Put options by funds: $655K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.15M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$4.34M |
| 4 |
Morgan Stanley
New York
|
+$3.05M |
| 5 |
BlackRock
New York
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$34M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.18M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$3.04M |
| 4 |
D.E. Shaw & Co
New York
|
-$420K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$201K |
PLRX Hedge Fund Activity: Q4 2021 in Review
88 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2021, worth a combined $416M — down 19% from $512M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PLRX positions and 7 closed out — a net gain of 11 holders — while 34 added to existing stakes and 13 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $18M. The largest seller was Eventide Asset Management, cutting an estimated $34M.
- 88 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2021, up from 77 in Q3 2021.
- Funds reported $416M of Pliant Therapeutics stock for Q4 2021, down 19% quarter-over-quarter.
- 18 funds opened new Pliant Therapeutics positions in Q4 2021 and 7 closed out, a net change of +11 holders.
- The largest Pliant Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $18M added.
- The largest Pliant Therapeutics seller in Q4 2021 was Eventide Asset Management, an estimated $34M sold.
Based on aggregated 13F filings for Q4 2021.